TARGETS

 

Master Invadopodia Regulator 2 (MIR-02)

MIR-02 is a transmembrane receptor that is predominantly localized to the surface of invadopodia on invasive cancer cells in different types of human cancers (Figure 1). MIR-02-expressing cancer cells are proficient in invadopodia formation and are highly invasive and pro-metastatic (Figure 2). Consistently, the expression of MIR-02 negatively correlates with the survival of patients in multiple types of metastatic cancers (Figure 3). Activation of MIR-02 by its ligand leads to the activation of multiple kinases, including Src, PKC, JNK, small GTPases, and an epithelial-mesenchymal-transition (EMT) to promote the functions of invadopodia, leading to cell invasiveness and cancer metastasis (Figure 4). As such, the genetic knockdown of MIR-02 blocks the formation of invadopodia in invasive cancer cells (Figure 5A), thereby inhibiting cancer invasiveness (Figure 5B) as well as the extravasation of cancer cells in vivo (Figure 6).

Figure 1. MIR-02 specifically localizes to the invadopodia in invasive cancer cells

Figure 1. MIR-2 is specifically localized to the invadopodia in invasive cancer cells

Figure 2. MIR-02-expressing cancer cells are proficient in generating invadopodia (A) and are highly invasive (B) and pro-metastatic (C)

Figure 3. Genetic knockdown of MIR-2 abrogates invadopodia formation in invasive cancer cells

Figure 3. MIR-02 expression correlates with shorter overall survival of cancer patients.

Figure 2. MIR-2 expression correlates with shorter overall survival of cancer patients.

Figure 4. Activation of MIR-2 by its ligand on invadopodia induces multiple downstream signaling events and cancer metastasis

Figure 2. MIR-2 expression correlates with shorter overall survival of cancer patients.

PKC, protein kinase C; JNK, c-Jun N-terminal kinase; EMT, epithelial-mesenchymal transition.

Figure 5. Genetic knockdown (KD) of MIR-02 inhibits invadopodia formation (A) and cancer cell invasion (B)

Figure 4. Genetic knockdown of MIR-2 abrogates cancer cell invasiveness

Figure 6. Genetic knockdown (KD) of MIR-02 inhibits cancer cell extravasation

Figure 4. Genetic knockdown of MIR-2 abrogates cancer cell invasiveness

GAC, gastric adenocarcinoma; Agglutinin, blood vessel marker.

Logo_vertical_light.png

Designed by Justin V. Tsai in 2021

Copyright © Antapodia Therapeutics, Inc., WA, USA. All Rights Reserved.

Search